Lundbeckfonden Ventures

Type

Venture Capital, Accelerator/Incubator

Status

Active

Location

Copenhagen, Denmark

Total investments

62

Average round size

31M

Portfolio companies

35

Rounds per year

4.43

Lead investments

12

Follow on index

0.44

Exits

17

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyDrug DiscoveryHealth CareManufacturingMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

In 2009 was created Lundbeckfonden Ventures, which is appeared as VC. The main office of represented VC is situated in the Copenhagen. The company was established in Europe in Denmark.

Besides them, we counted 3 critical employees of this fund in our database.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Lundbeckfonden Ventures, startups are often financed by New Enterprise Associates, SR One, TPG Biotech. The meaningful sponsors for the fund in investment in the same round are Pfizer Venture Investments, Seventure Partners, OUP (Osage University Partners). In the next rounds fund is usually obtained by OUP (Osage University Partners), New Enterprise Associates, SR One.

Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Among the various public portfolio startups of the fund, we may underline DBV Technologies, SNIPR Biome, Cydan Among the most successful fund investment fields, there are Biotechnology, Therapeutics.

The higher amount of exits for fund were in 2017. The fund is constantly included in 2-6 investment rounds annually. The important activity for fund was in 2016. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 16 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Lundbeckfonden Ventures performs on 1 percentage points less the average number of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesHealthcare
Geo focus
Denmark

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
62
Lead investments
12
Exits
17
Rounds per year
4.43
Follow on index
0.44
Investments by industry
  • Biotechnology (56)
  • Health Care (34)
  • Therapeutics (27)
  • Pharmaceutical (18)
  • Medical (17)
  • Show 16 more
Investments by region
  • United States (33)
  • France (7)
  • United Kingdom (8)
  • Spain (2)
  • Netherlands (2)
  • Show 4 more
Peak activity year
2016

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
12
Avg. valuation at time of investment
10M
Group Appearance index
0.95
Avg. company exit year
8
Avg. multiplicator
0.55

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Amplyx Pharmaceuticals 01 Aug 2017 Biotechnology, Medical, Pharmaceutical, Clinical Trials Late Stage Venture 67M United States, California, San Diego
Coverage Cat 03 Aug 2022 Financial Services, Insurance Seed
Vcare Technologies P. Ltd (Diro Labs - phonebooks) 10 Jun 2019 Internet, Information Technology, Mobile Apps Seed 0 India, Delhi, New Delhi
VarmX 25 May 2023 Manufacturing, Pharmaceutical, Therapeutics Early Stage Venture 41M South Holland, Leiden, Netherlands

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.